Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01590888Phase 2Completed

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

Role: lead

NCT02109497Phase 1Completed

Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine

Role: lead

NCT02107313Phase 1Completed

Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2

Role: lead

NCT02249728Phase 1Completed

Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2

Role: lead

NCT00471211Phase 2Completed

Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease

Role: lead

All 5 trials loaded